Common Sensing, a Cambridge, MA-based evidence-based, data-driven injectable-medicine healthcare company, closed a $6.6m USD Series A financing.
The round was led by Waterline Ventures, with participation from New World Health, Royal Philips (NYSE: PHG; AEX: PHIA), and Haselmeier.
The company will use the funds to accelerate its manufacturing and commercial operations for Gocap™.
Co-founded in 2012 by James White and Richard Whalley, and also led by Kevin Schmid, Chief Operating Officer, Common Sensing is advancing a smart cap that tracks, logs and manages injectable dosage, timing, and storage information to get a complete picture of how people use injectable medicine at home and on-the-go. Gocap, an IP-protected dose monitoring solution, enables patients and providers to utilize injectable medicine, including insulin, fertility medications, growth hormones, and others. It offers data-driven services, including remote disease management, pharmaceutical support, automatic refills, dose titration, and caretaker collaboration.